Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGFβ depletion

Sophia Y Chen,Heng-Chung Kung,Birginia Espinoza,India Washington,Kai Chen,Jianxin Wang,Haley Zlomke,Michael A Loycano,Rulin Wang,Michael Pickup,William R Burns Iii,Juan Fu,William L Hwang,Lei Zheng

DOI: https://doi.org/10.1172/jci.insight.182766

IF: 9.4958

2024-09-19

JCI Insight

Abstract:The dual tumor-suppressive and promoting function of TGFβ signaling has made its targeting challenging. We hereby examined the effects of TGFβ depletion by AVID200/BMS-986416(TGFβ-TRAP), a TGFβ ligand trap, on the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) murine models with different organ-specific metastasis. Our study demonstrated that TGFβ-TRAP potentiates the efficacy of anti-PD-1 in a PDAC orthotopic murine model with liver metastasis tropism, significantly reducing liver metastases. We further demonstrated the heterogeneous response of cytotoxic effector T-cells to combination TGFβ-TRAP and anti-PD-1 treatment across several tumor models. Single-nuclear RNA-sequencing suggested that TGFβ-TRAP modulates cancer associated fibroblast (CAF) heterogeneity and suppresses neutrophil degranulation and CD4+ T-cell response to neutrophil degranulation. Ligand-receptor analysis indicated that TGFβ-TRAP may modulate the CCL5-CCR5 axis as well as co-stimulatory and checkpoint signaling from CAFs and myeloid cells. Notably, the most highly expressed ligands of CCR5 shifted from the immunosuppressive CCL5 to CCL7 and CCL8, which may mediate the immune agonist activity of CCR5 following TGFβ-TRAP and anti-PD-1 combination treatment. This study suggested that TGFβ depletion modulates CAF heterogeneity and potentially reprograms CAFs and myeloid cells into anti-tumor immune agonists in PDAC, supporting the validation of such effects in human specimen.